Literature DB >> 3993391

Rapid formation of reduced haloperidol in guinea pigs following haloperidol administration.

E R Korpi, D T Costakos, R J Wyatt.   

Abstract

Haloperidol, a butyrophenone neuroleptic, is metabolically reduced in man, but not in rat and not in many other experimental animals. Here we present data that describes reductive haloperidol metabolism in guinea pigs in vivo. When haloperidol was injected intraperitoneally to guinea pigs, it was converted to reduced haloperidol so quickly that 1 hr after the injection the concentration of haloperidol was only about one fifth of that of reduced haloperidol. Dopamine metabolism was enhanced in the striatum after the administration of reduced haloperidol, but this enhancement could mostly be explained by oxidation of a small amount of reduced haloperidol back to haloperidol. The molecular mechanisms of haloperidol reduction should be further studied using guinea pigs as a model for human haloperidol metabolism.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3993391     DOI: 10.1111/j.1600-0773.1985.tb01260.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  7 in total

Review 1.  Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?

Authors:  W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients.

Authors:  M W Jann; Y W Lam; W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Biliary excretion of reduced haloperidol glucuronide.

Authors:  N D Eddington; D Young
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).

Authors:  R F Tyndale; W Kalow; T Inaba
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

5.  Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in guinea pigs.

Authors:  W H Chang; S S Jaw; H S Wu; L Tsay; E K Yeh
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 6.  Pharmacokinetics of haloperidol.

Authors:  J S Froemming; Y W Lam; M W Jann; C M Davis
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

7.  Determination of oxidative stress and activities of antioxidant enzymes in guinea pigs treated with haloperidol.

Authors:  Jaromir Gumulec; Martina Raudenska; Marian Hlavna; Tibor Stracina; Marketa Sztalmachova; Veronika Tanhauserova; Lukas Pacal; Branislav Ruttkay-Nedecky; Jiri Sochor; Ondrej Zitka; Petr Babula; Vojtech Adam; Rene Kizek; Marie Novakova; Michal Masarik
Journal:  Exp Ther Med       Date:  2012-11-20       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.